ArticleBiopolymers2026
Biogenic Silver Nanoparticles-Loaded Collagen-L-Lysine Matrices in Gel and Spray Formulations for Improved Skin Wound Repair.
Article in Biopolymers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Biogenic silver nanoparticles (AgNPs) are emerging as valuable candidates in biomedical research, offering advantages such as cost-effectiveness, eco-friendly preparation methods, and superior biocompatibility. Owing to the challenges in the treatment of chronic skin injury, this study utilizes biogenic AgNPs (synthesized using Shilajit as a reducing and stabilizing agent) to develop gel and spray formulations (constituting fish collagen and l-lysine) for wound-healing applications. FTIR analysis indicated the involvement of functional groups from the Shilajit extract in synthesizing crystalline spherical AgNPs of 140-160 nm diameter. EDAX analysis reported 0.6% (by weight) silver in both formulations, with major elemental peaks for nitrogen, carbon, and oxygen, indicating the presence of polysaccharides. The MTT assay on HDFa cells confirmed that both preparations were nontoxic, as validated by FDA staining, which signified intact cell morphology. In vivo findings demonstrated that ShilAgNPs-Fcol-Lys formulations promote rapid wound closure, effective extracellular matrix (ECM) deposition, advanced neovascularization, and improved tissue remodeling compared with controls and standard treatments. Well-organized collagen deposition and efficient remodeling were confirmed by histology and immunohistochemistry, with the spray formulation performing better than the gel. Thus, ShilAgNPs-Fcol-Lys formulations offer a biocompatible, safe, and cost-effective alternative for treating deep excisional wounds.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.